Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants.

Next Previous
X
Search
Trial Profile

Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 257049 (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Measles virus vaccine live; Poliovirus vaccine live oral; Yellow fever vaccine
  • Indications Diphtheria; Falciparum malaria; Haemophilus infections; Hepatitis B; Measles; Pertussis; Poliomyelitis; Tetanus; Yellow fever
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 20 Oct 2009 Actual patient number (511) added as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top